Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 | Dec-31-00 | Dec-31-99 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Life sciences research | 118.2 | 108.9 | 87.4 | 63.7 | 56.3 | 48.4 | 46.9 | 38.7 |
| North America | 103.3 | 106.3 | 91.0 | 72.4 | 64.8 | 61.6 | 63.5 | 47.0 |
| Drug discovery | 68.2 | 73.1 | 61.7 | 51.9 | 45.8 | 43.9 | 49.2 | 33.2 |
| Europe | 49.2 | 46.2 | 38.5 | 28.1 | 25.3 | 20.1 | 25.4 | 19.3 |
| Total revenues | 186.4 | 182.0 | 149.1 | 115.6 | 102.2 | 92.2 | 96.0 | 71.9 |
| Revenue growth [+] | 2.5% | 22.0% | 29.0% | 13.1% | 10.8% | -4.0% | 33.6% | |
| Life sciences research | 8.6% | 24.6% | 37.2% | 13.1% | 16.5% | 3.2% | 21.0% | |
| North America | -2.8% | 16.8% | 25.7% | 11.7% | 5.1% | -2.9% | 35.1% | |
| Drug discovery | -6.7% | 18.5% | 18.9% | 13.2% | 4.5% | -10.8% | 48.2% | |
| Europe | 6.4% | 20.0% | 37.1% | 10.9% | 25.8% | -20.7% | 31.2% | |
| Rest of World | 15.3% | 50.4% | 29.6% | 25.7% | 14.9% | 45.5% | 28.4% | |
| Cost of goods sold | 70.1 | 70.3 | 56.8 | 43.3 | 40.6 | 35.5 | 35.6 | 26.3 |
| Gross profit | 116.3 | 111.7 | 92.3 | 72.3 | 61.6 | 56.7 | 60.5 | 45.6 |
| Gross margin | 62.4% | 61.4% | 61.9% | 62.6% | 60.3% | 61.5% | 62.9% | 63.4% |
| Selling, general and administrative | 71.8 | 59.9 | 52.5 | 43.5 | 35.4 | 33.4 | 31.9 | 25.6 |
| Research and development | 23.4 | 25.3 | 22.0 | 18.7 | 18.0 | 15.1 | 16.8 | 14.2 |
| EBITDA [+] | 31.4 | 36.0 | 24.8 | 15.9 | 12.3 | 11.9 | 13.8 | 7.2 |
| EBITDA growth | -13.0% | 45.3% | 55.9% | 29.6% | 3.1% | -13.8% | 93.3% | |
| EBITDA margin | 16.8% | 19.8% | 16.6% | 13.8% | 12.0% | 12.9% | 14.4% | 9.9% |
| Depreciation | 6.4 | 6.5 | 5.8 | 5.3 | 3.8 | 3.7 | 2.1 | 1.3 |
| EBITA | 24.9 | 29.6 | 19.0 | 10.6 | 8.4 | 8.2 | 11.8 | 5.8 |
| EBITA margin | 13.4% | 16.2% | 12.7% | 9.2% | 8.3% | 8.9% | 12.2% | 8.1% |
| Amortization of intangibles | 3.8 | 3.0 | 1.2 | 0.4 | 0.3 | | | |
| EBIT [+] | 21.2 | 26.5 | 17.7 | 10.2 | 8.2 | 8.2 | 11.8 | 5.8 |
| EBIT growth | -20.2% | 49.4% | 74.2% | 24.9% | -0.6% | -30.2% | 101.8% | |
| EBIT margin | 11.4% | 14.6% | 11.9% | 8.8% | 8.0% | 8.9% | 12.2% | 8.1% |
| Non-recurring items | 4.6 | 1.4 | 6.2 | | | 12.6 | 15.2 | 2.0 |
| Interest expense | 0.1 | 0.1 | 0.2 | | | | | |
| Interest expense | 0.1 | 0.1 | 0.2 | | | | | |
| Other income (expense), net | 4.2 | -0.5 | 18.6 | 0.9 | 1.6 | 3.8 | 4.9 | 1.9 |
| Pre-tax income | 20.6 | 24.5 | 30.0 | 11.1 | 9.7 | -0.6 | 1.5 | 5.7 |
| Income taxes | 9.8 | 8.6 | 12.8 | 3.3 | 2.9 | 4.6 | 6.4 | 2.1 |
| Tax rate | 47.6% | 35.1% | 42.6% | 30.0% | 30.0% | | 433.2% | 36.0% |
| Net income | 10.8 | 15.9 | 17.2 | 7.7 | 6.8 | -5.2 | -4.9 | 3.7 |
| Net margin | 5.8% | 8.7% | 11.6% | 6.7% | 6.7% | -5.7% | -5.1% | 5.1% |
| |
| Basic EPS [+] | $0.65 | $0.95 | $1.08 | $0.51 | $0.44 | ($0.32) | ($0.32) | $0.27 |
| Growth | -31.6% | -12.0% | 111.8% | 15.9% | -237.5% | 0.0% | -218.5% | |
| Diluted EPS [+] | $0.64 | $0.93 | $1.04 | $0.51 | $0.44 | ($0.32) | ($0.32) | $0.26 |
| Growth | -31.2% | -10.6% | 103.9% | 15.9% | -237.5% | 0.0% | -223.1% | |
| |
| Shares outstanding (basic) [+] | 16.7 | 16.7 | 16.0 | 15.2 | 15.5 | 16.4 | 15.4 | 13.5 |
| Growth | -0.5% | 4.9% | 5.1% | -1.8% | -5.5% | 6.1% | 14.0% | |
| Shares outstanding (diluted) [+] | 16.9 | 17.1 | 16.6 | 15.2 | 15.5 | 16.4 | 15.4 | 14.0 |
| Growth | -1.0% | 3.2% | 9.2% | -1.8% | -5.5% | 6.1% | 9.8% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|